Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 October 2007, Vol. 110, No. 7, pp. 2286-2295.
Prepublished online as a Blood First Edition Paper on August 1, 2007; DOI 10.1182/blood-2007-04-084996.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-04-084996v1
blood-2007-04-084996v2
110/7/2286    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ahn, K. S.
Right arrow Articles by Aggarwal, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahn, K. S.
Right arrow Articles by Aggarwal, B. B.
Related Collections
Right arrow Hematopoiesis and Stem Cells
Right arrow Apoptosis
Right arrow Chemokines, Cytokines, and Interleukins
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CHEMOKINES, CYTOKINES, AND INTERLEUKINS

Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-{kappa}B–regulated gene products

Kwang Seok Ahn1, Gautam Sethi1, Ta-Hsiang Chao2, Saskia T. C. Neuteboom2, Madan M. Chaturvedi1,3, Michael A. Palladino2, Anas Younes4, and Bharat B. Aggarwal1

1 Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston; 2 Nereus Pharmaceuticals, San Diego, CA; 3 Department of Zoology, University of Delhi, Delhi, India, and 4 Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston

Salinosporamide A (also called NPI-0052), recently identified from the marine bacterium Salinispora tropica, is a potent inhibitor of 20S proteasome and exhibits therapeutic potential against a wide variety of tumors through a poorly understood mechanism. Here we demonstrate that salinosporamide A potentiated the apoptosis induced by tumor necrosis factor {alpha} (TNF), bortezomib, and thalidomide, and this correlated with down-regulation of gene products that mediate cell proliferation (cyclin D1, cyclooxygenase-2 [COX-2], and c-Myc), cell survival (Bcl-2, Bcl-xL, cFLIP, TRAF1, IAP1, IAP2, and survivin), invasion (matrix metallopro-teinase-9 [MMP-9] and ICAM-1), and angiogenesis (vascular endothelial growth factor [VEGF]). Salinosporamide A also suppressed TNF-induced tumor cell invasion and receptor activator of nuclear factor {kappa}B ligand (RANKL)-induced osteoclastogenesis. We also found that it suppressed both constitutive and inducible NF-{kappa}B activation. Compared with bortezomib, MG-132, N-acetyl-leucyl-leucyl-norleucinal (ALLN), and lactacystin, salinosporamide A was found to be the most potent suppressor of NF-{kappa}B activation. Further studies showed that salinosporamide A inhibited TNF-induced inhibitory subunit of NF-{kappa}B {alpha} (I{kappa}B{alpha}) degradation, nuclear translocation of p65, and NF-{kappa}B-dependent reporter gene expression but had no effect on I{kappa}B{alpha} kinase activation, I{kappa}B{alpha} phosphorylation, or I{kappa}B{alpha} ubiquitination. Thus, overall, our results indicate that salinosporamide A enhances apoptosis, suppresses osteoclastogenesis, and inhibits invasion through suppression of the NF-{kappa}B pathway.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
B. B. Aggarwal, R.V. Vijayalekshmi, and B. Sung
Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe
Clin. Cancer Res., January 15, 2009; 15(2): 425 - 430.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Baritaki, E. Suzuki, K. Umezawa, D. A. Spandidos, J. Berenson, T. R. Daniels, M. L. Penichet, A. R. Jazirehi, M. Palladino, and B. Bonavida
Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells
J. Immunol., May 1, 2008; 180(9): 6199 - 6210.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020